SCHEMBL17622504

SCHEMBL17622504

CCOC(=O)c1c(Cl)ccnc1N

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM6 O15303 1/20 0.45
HSD17B10 Q99714 4/20 0.45
ALDH1A1 P00352 3/20 0.45
HPGD P15428 2/20 0.45
KDM4E B2RXH2 2/20 0.45
TP53 P04637 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
RAB9A P51151 1/20 0.45
LMNA P02545 3/20 0.44
PKM P14618 1/20 0.44
PRKCZ Q05513 1/20 0.44
CYP1A2 P05177 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31151022 0.84 PDE4B (0.48) HSD17B10ALDH1A1HPGDKDM4ETP53
SCHEMBL30666434 0.84 CA12 (0.47) GRM6HSD17B10ALDH1A1HPGDKDM4E
SCHEMBL320812 0.84 CA12 (0.47) GRM6HSD17B10ALDH1A1HPGDKDM4E
SCHEMBL8840548 0.84 PDE4B (0.48) HSD17B10ALDH1A1HPGDKDM4ETP53
SCHEMBL31468929 0.83 TP53 (0.41) GRM6HSD17B10ALDH1A1HPGDKDM4E
SCHEMBL4231441 0.82 ALDH1A1 (0.41) HSD17B10ALDH1A1HPGDKDM4ETP53
SCHEMBL25303508 0.82 DPP4 (0.43) GRM6HSD17B10ALDH1A1HPGDKDM4E
SCHEMBL843997 0.81 ADORA3 (0.47) GRM6HSD17B10ALDH1A1HPGDKDM4E
SCHEMBL844466 0.81 CA12 (0.45) GRM6HSD17B10ALDH1A1HPGDKDM4E
SCHEMBL23923034 0.81 MAPT (0.47) HSD17B10ALDH1A1HPGDKDM4ETP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3727435-B1 BIVALENT NUCLEIC ACID LIGANDS AND USES THEREFOR UNIV CARNEGIE MELLON (US) 2026-02-18 EP disclosed
CN-111757935-B Bivalent nucleic acid ligands and uses thereof 卡耐基梅隆大学 2025-02-21 CN disclosed
EP-3727435-A1 BIVALENT NUCLEIC ACID LIGANDS AND USES THEREFOR CARNEGIE MELLON UNIVERSITY (US) 2020-10-28 EP disclosed
CN-111757935-A Bivalent nucleic acid ligand and use thereof 卡耐基梅隆大学 2020-10-09 CN disclosed
US-20200318195-A1 Bivalent Nucleic Acid Ligands and Uses Therefor CARNEGIE MELLON UNIVERSITY 2020-10-08 US disclosed
US-20200318195-A1 Bivalent Nucleic Acid Ligands and Uses Therefor CARNEGIE MELLON UNIVERSITY 2020-10-08 US disclosed
US-10370415-B2 Divalent nucleobase compounds and uses therefor CARNEGIE MELLON UNIVERSITY (US) 2019-08-06 US disclosed
US-20160083434-A1 DIVALENT NUCLEOBASE COMPOUNDS AND USES THEREFOR CARNEGIE MELLON UNIVERSITY (US) 2016-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160083434-A1 DIVALENT NUCLEOBASE COMPOUNDS AND USES THEREFOR DNTT, POLM, POLL GRM6 3716/4885HSD17B10 4708/4885ALDH1A1 4313/4885
US-10370415-B2 Divalent nucleobase compounds and uses therefor DNTT, POLM, POLL GRM6 3716/4885HSD17B10 4708/4885ALDH1A1 4313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.